Medpace (NASDAQ:MEDP) Issues FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 16.680-17.500 for the period, compared to the consensus estimate of 15.830. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.7 billion.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $446.05 on Wednesday. The stock’s 50 day moving average price is $575.55 and its 200 day moving average price is $539.56. The stock has a market cap of $12.57 billion, a price-to-earnings ratio of 29.15, a PEG ratio of 1.78 and a beta of 1.42. Medpace has a 12 month low of $250.05 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 127.72% and a net margin of 17.83%.The company’s revenue was up 32.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts expect that Medpace will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Mizuho set a $660.00 price target on shares of Medpace in a research report on Friday, January 9th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Leerink Partners decreased their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $499.45.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 296,880 shares of company stock worth $178,815,404. Corporate insiders own 20.30% of the company’s stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q4 beat on revenue and EPS — Medpace reported $708.5M revenue and $4.67 EPS, topping expectations and showing 32% YoY revenue growth; the strong quarter underpins organic demand for CRO services. Medpace Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Raised FY2026 guidance — Medpace set EPS guidance of $16.68–$17.50 and revenue guidance of $2.8B–$2.9B, above consensus, signaling management expects continued top-line growth despite some near-term headwinds. Medpace FY2026 Guidance
• Positive Sentiment: New CRO win — Zelluna selected Medpace as CRO for its ZIMA-101 first-in-human trial, adding client work that supports future service revenue. Zelluna selects Medpace as CRO
• Positive Sentiment: Analyst upgrade — Robert W. Baird upgraded MEDP to Outperform with a $564 PT, signaling increased analyst conviction and potential catalyst for buying interest. Baird upgrades Medpace
• Neutral Sentiment: Investor materials and call transparency — Earnings call transcript and slide deck are available for details on bookings, backlog and margin drivers; useful for modeling but not immediate catalysts. Earnings call transcript
• Negative Sentiment: Backlog normalization and trial timing drove the selloff — Despite the beat, investors reacted to management commentary about backlog growth slowing and timing shifts in metabolic trials, which compress near-term revenue visibility and prompted a roughly 5% intraday drop. Medpace shares tumble despite Q4 beat

Hedge Funds Weigh In On Medpace

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC boosted its holdings in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Wasatch Advisors LP grew its holdings in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Invesco Ltd. raised its position in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the period. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Medpace by 1,527.8% in the third quarter. Qube Research & Technologies Ltd now owns 74,780 shares of the company’s stock worth $38,449,000 after buying an additional 70,186 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.